20 June 2013
Keywords: memory, doses, first, schizophrenia, patient, trial, usa
Article | 12 January 2009
The USA's Memory Pharmaceuticals has dosed the first patient in a Phase II study of the effect of R3487/MEM 3454, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 January 2009
19 June 2013
© 2013 thepharmaletter.com